What moved IHL.AX stock intraday today?

IHL.AX stock moved on Phase 2 efficacy data for IHL-42X and a US$10.0 million registered direct offering that funds the next study. High volume reflects increased buying and short-term trading around these catalysts.

How does the financing affect IHL.AX stock prospects?

The US$10.0 million financing secures funding for the DReAMzz Phase 2 study, reducing near-term cash risk. Full warrant exercise could add further capital but may dilute shareholders if exercised.

What are the key risks for IHL.AX stock?

Key risks include binary clinical outcomes, regulatory setbacks, and potential dilution from future equity raises. Low float and small market cap add volatility to IHL.AX stock price moves.

What is Meyka AI's view on IHL.AX stock?

Meyka AI rates IHL.AX 64.99/100 (Grade B, HOLD). The model projects a base-case of A$0.12 for IHL.AX stock, but notes forecasts are model-based and not guarantees.

AU Stocks

IHL.AX Incannex Healthcare (ASX) A$0.041 intraday 13 Mar 2026: Phase 2 news drives volume

ByHuzaifa Zahoor March 13, 2026March 13, 2026

IHL.AX stock opened the ASX session at A$0.047 and trades A$0.041 intraday on 13 Mar 2026 as volume spikes to 61,360,016 shares. The move follows two company announcements: statistically significant Phase 2 results for IHL-42X and a US$10.0 million registered direct offering that funds the next dose-optimization study. Traders are watching clinical milestones and cash runway closely today. We track price action, fundamentals and catalysts for short-term and multi-stage investors.